Although most commonly a disease of the old, Acute Myeloid Leukaemia is also a significant burden for younger patients, but it can present in different ways and they should not be treated equal. So how should younger and older patients be classified and treated? To help answer some of our questions on this topic is Dr. Tapan Kadia, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

References

• Public Health England. NCIN. 2015: 2013548
• Tarlock, et al. Pediatr Clin North Am. 2015 Feb;62(1):75-93
• Vakiti and Mewawalla. StatPearls: StatPearls Publishing; 2020 Jan
• PDQ Pediatric Treatment Editorial Board. Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®): Health Professional Version. 2020 Aug 20
• Bolouri. et al. Nat Med. 2018 Jan; 24(1): 103–112
• Silva, et al. Leukemia. 2017 Jul;31(7):1640-1644
• Nagal, et al. Ann Hematol. 2017; 96(12): 1993–2003
• Creutzig, et al. Blood. 2012 Oct 18;120(16):3187-205
• Sekeres, et al. Blood Adv. 2020 Aug 11;4(15):3528-3549
• Heuser et al. Ann Oncol. 2020 Mar 17;S0923-7534(20)36079-8
• Joon Im. Blood Res. 2018 Mar; 53(1): 1–2

This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty.